MedTrace Logo

Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis

NCT06565845 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2024-08-22

No results posted yet for this study

Summary

Granulomatous lobular mastitis (GLM) is a rare benign breast disease that is difficult to distinguish from breast cancer based on clinical and imaging findings, and there is currently no standard treatment. This study aims to analyze the clinical characteristics and demographic data of GLM patients and to compare the overall effectiveness of three treatment methods: surgery alone, triple anti-tuberculosis drug therapy alone, and combined surgery with triple anti-tuberculosis drug therapy, with the goal of providing new insights for clinical treatment.

Conditions

  • Granulomatous Mastitis

Interventions

PROCEDURE

Surgery

patients underwent complete excision of the inflammatory breast tissue and some surrounding normal tissue under combined intravenous with inhalation anesthesia. Damaged skin was also removed.

DRUG

triple anti-tuberculosis drug

Patients took oral rifampin (450 mg/day), isoniazid (300 mg/day), and ethambutol (15 mg/kg/day).

Sponsors & Collaborators

  • First Affiliated Hospital of Harbin Medical University

    lead OTHER

Principal Investigators

  • Jing Feng · First Affiliated Hospital of Harbin Medical University

Eligibility

Min Age
15 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-19
Primary Completion
2024-09-19
Completion
2024-10-19

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06565845 on ClinicalTrials.gov